Available Until 5/13/2023

COVID-19: Remdesivir: Early Use in Search for its Niche

Activity Type: Knowledge-based  
CE Credit: No CE is offered with this activity.
Activity Fee: Members/Non-Members - Free
Activity Date: May 8, 2020


Remdesivir has been added to the FDA Emergency Use Authorization list for the treatment of hospitalized patients with severe COVID-19 disease. Hear about drug information, supply chain considerations, investigational drug services, and regulatory/safety issues, and clinical experience with remdesivir.

Learn about early information on the clinical use of and access to remdesivir for treatment of patients with COVID-19. Topics that will be covered in this first installment include practical and operational aspects and clinical pearl perspectives. 

Learning Objectives

  • Collection of Evidence and Remdesivir Monograph Development 
  • Distribution of Remdesivir and Supply Chain Considerations
  • Investigational Drug Services, Dose Conservation, and Clinical Experience with Remdesivir


Kevin E. Anger, Pharm.D., BCPS
Pharmacy Supervisor, Investigational Drug Services 
Department of Pharmacy 
Brigham and Women's Hospital 
Boston, MA  

Michael Ganio, Pharm.D., M.S., BCPS, FASHP 
Senior Director, Pharmacy Practice and Quality
American Society of Health System Pharmacists

Cindy Huang, Pharm.D.
Assistant Editor, AHFS
AHFS Drug Information
American Society of Health System Pharmacists

Elaine Snow, BS Pharm. 
Editor-in-Chief, AHFS Drug Information® (AHFS® DI™) and Handbook on Injectable Drugs® (HID™), 
American Society of Health System Pharmacists


The webinar will be moderated by Eric Maroyka, ASHP's Senior Director, Center on Pharmacy Practice Advancement, and Erika Thomas, ASHP's Director, Section of Inpatient Care Practitioners.